Table 4.
Subgroup analyses of NLR for OS and PFS
| OS | PFS | P H | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | HR | 95% CI | P | I-squared | P H | No. | HR | 95% CI | P | I-squared | ||
| Ethnicity | ||||||||||||
| Asian | 10 | 1.83 | 1.52–2.21 | 0.000 | 0.0% | 0.715 | 5 | 1.59 | 1.23–2.06 | 0.000 | 0.0% | 0.436 |
| Other | 16 | 1.45 | 1.26–1.66 | 0.000 | 86.6% | 0.000 | 7 | 1.62 | 1.18–2.23 | 0.003 | 79.7% | 0.000 |
| Patients status | ||||||||||||
| mCRPC | 13 | 1.70 | 1.52–1.90 | 0.000 | 17.7% | 0.265 | 6 | 1.62 | 1.33–1.98 | 0.000 | 45.3% | 0.140 |
| CRPC | 5 | 1.86 | 1.40–2.48 | 0.000 | 0.0% | 0.716 | 4 | 1.76 | 1.18–2.62 | 0.006 | 28.5% | 0.221 |
| Localized PCa | 3 | 1.10 | 0.93–1.31 | 0.274 | 71.7% | 0.029 | 1 | 3.09 | 1.64–5.82 | 0.000 | – | – |
| All PCa | 5 | 1.20 | 1.02–1.41 | 0.026 | 53.5% | 0.072 | 1 | 0.84 | 0.74–1.19 | 0.603 | – | – |
| Sample size | ||||||||||||
| ≤ 300 | 15 | 1.73 | 1.40–2.16 | 0.002 | 59.6% | 0.598 | 9 | 1.51 | 1.13–2.01 | 0.005 | 58.7% | 0.013 |
| > 300 | 11 | 1.45 | 1.23–1.71 | 0.000 | 89.5% | 0.000 | 3 | 1.88 | 1.32–2.67 | 0.000 | 73.5% | 0.023 |
| Follow time | ||||||||||||
| ≤ 30 | 12 | 1.74 | 1.55–1.95 | 0.000 | 0.0% | 0.748 | 7 | 1.77 | 1.39–2.27 | 0.000 | 45.3% | 0.089 |
| > 30 | 7 | 1.15 | 1.02–1.30 | 0.020 | 75.2% | 0.000 | 3 | 1.59 | 0.77–3.28 | 0.212 | 84.8% | 0.001 |
| Unclear | 7 | 1.58 | 1.39–1.80 | 0.000 | 0.0% | 0.430 | 2 | 1.36 | 1.00–1.88 | 0.061 | 0.0% | 0.700 |
| Cut-off | ||||||||||||
| ≤ 3 | 10 | 1.75 | 1.57–1.97 | 0.000 | 0.0% | 0.014 | 5 | 1.81 | 1.36–2.42 | 0.000 | 51.2% | 0.085 |
| > 3 | 12 | 1.63 | 1.32–2.00 | 0.000 | 53.8% | 0.444 | 7 | 1.50 | 1.09–2.07 | 0.014 | 68.5% | 0.004 |
| No | 4 | 1.14 | 0.97–1.34 | 0.101 | 88.5% | 0.000 | 0 | – | – | – | – | – |
| Study design | ||||||||||||
| Retrospective | 21 | 1.63 | 1.39–1.91 | 0.000 | 84.0% | 0.000 | 9 | 1.74 | 1.42–2.13 | 0.000 | 25.3% | 0.219 |
| Prospective | 5 | 1.36 | 1.10–1.68 | 0.005 | 66.7% | 0.017 | 3 | 1.42 | 0.89–2.26 | 0.144 | 84.3% | 0.002 |
| Statistical method | ||||||||||||
| Multivariable | 22 | 1.54 | 1.34–1.77 | 0.000 | 79.5% | 0.000 | 10 | 1.65 | 1.22–2.24 | 0.001 | 66.3% | 0.002 |
| Univariable | 4 | 1.56 | 1.17–2.10 | 0.003 | 85.9% | 0.000 | 2 | 1.66 | 1.20–2.30 | 0.002 | 74.1% | 0.049 |
| Therapy | ||||||||||||
| Surgery | 5 | 1.12 | 0.99–1.26 | 0.072 | 72.7% | 0.005 | 2 | 1.64 | 0.51–5.26 | 0.404 | 91.6% | 0.001 |
| Chemotherapy | 18 | 1.69 | 1.53–1.84 | 0.000 | 1.2% | 0.440 | 10 | 1.64 | 1.38–1.95 | 0.000 | 27.8% | 0.188 |
| Radiotherapy | 1 | 1.10 | 0.95–1.27 | 0.198 | – | – | – | – | – | – | – | – |
| Others | 2 | 1.63 | 1.07–2.47 | 0.022 | 0.0% | 0.638 | – | – | – | – | – | – |
OS, overall survival; PFS, progression-free survival; NLR, neutrophil to lymphocyte ratios; mCRPC, metastatic castration-resistant prostate cancer; PCa, prostate cancer; HR, hazard ratio; CI, confidence intervals; PH, heterogeneity of P-value